Challenges in Patient Enrollment and Retention in Clinical Studies for Alcoholic Hepatitis: Experience of the TREAT Consortium

被引:24
作者
Comerford, Megan [1 ]
Lourens, Spencer [2 ,3 ]
Liangpunsakul, Suthat [1 ,4 ]
Chalasani, Naga P. [1 ]
Sanyal, Arun J. [5 ]
Shah, Vijay H. [6 ]
Kamath, Patrick S. [6 ]
Puri, Puneet [5 ]
Katz, Barry P. [2 ,3 ]
Radaeva, Svetlana [7 ]
Crabb, David W. [1 ,8 ]
机构
[1] Indiana Univ Sch Med, Dept Med, Div Gastroenterol & Hepatol, 702 Rotary Circle,Suite 225, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA
[3] Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN USA
[4] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA
[5] Virginia Commonwealth Univ, Dept Med, Div Gastroenterol & Hepatol, Med Coll Virginia Campus, Richmond, VA 23298 USA
[6] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[7] NIAAA, NIH, Rockville, MD 20852 USA
[8] Eskenazi Hlth, Indianapolis, IN USA
关键词
Alcoholic Hepatitis; Recruitment; Retention; Clinical Trial; Model for End-Stage Liver Disease Score; PNPLA3; BACLOFEN; VARIANT;
D O I
10.1111/acer.13515
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The TREAT Consortium has carried out clinical studies on alcoholic hepatitis (AH) for over 4years. We encountered problems with participant recruitment, retention, and eligibility for specific protocols. To improve our ability to carry out such trials, we reviewed recruitment screening logs, end of study logs, and surveyed study coordinators to learn the reasons for missing patients, why patients declined enrollment, and the number of patients eligible for treatment trials. Associations of the recruited subjects' demographics with their adherence to follow-up appointments were examined. Three hundred eight-seven patients (AH and heavy drinking controls) were enrolled in the observational study, and 55 AH patients were recruited into treatment trials. About half of patients identified with AH could not be recruited; no specific reason could be determined for about two-thirds of these. Among the patients who gave a reason for not participating, the most common reasons were feeling too sick to participate, desire to concentrate on abstinence, and lack of interest in research. Approximately a quarter of the AH patients met eligibility criteria for treatment trials for moderate or severe AH and we were able to recruit half to two-thirds of those eligible. Approximately 35% of participants in the observational study returned for both 6- and 12-month follow-up visits. We did not identify biopsychosocial or demographic correlates of retention in the study. This analysis revealed that attempts at recruitment into trials for AH miss some subjects because of structural issues surrounding their hospital admission, and encounter a high rate of patient refusal to participate. Nonetheless, more than half of the patients who met the eligibility criteria for moderate or severe AH were entered into clinical trials. Retention rates for the observational study are relatively low. These findings need to be accounted for in clinical trial design and power analysis. Recruitment and retention of patients with alcohol use disorders in clinical trials is difficult; we report factors related to recruitment of patients with alcoholic hepatitis into observational and treatment trials. Approximately 35% of patients in the observational study returned for 6 and 12months followup visits. We did not identify any biopsychosocial correlates of retention. Half of the patients eligible for the treatment trials could be recruited. These data may guide design, power analyses, and execution of future studies.
引用
收藏
页码:2000 / 2006
页数:7
相关论文
共 12 条
[1]   Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study [J].
Addolorato, Giovanni ;
Leggio, Lorenzo ;
Ferrulli, Anna ;
Cardone, Silvia ;
Vonghia, Luisa ;
Mirijello, Antonio ;
Abenavoli, Ludovico ;
D'Angelo, Cristina ;
Caputo, Fabio ;
Zambon, Antonella ;
Haber, Paul S. ;
Gasbarrini, Giovanni .
LANCET, 2007, 370 (9603) :1915-1922
[2]   A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis [J].
Buch, Stephan ;
Stickel, Felix ;
Trepo, Eric ;
Way, Michael ;
Herrmann, Alexander ;
Nischalke, Hans Dieter ;
Brosch, Mario ;
Rosendahl, Jonas ;
Berg, Thomas ;
Ridinger, Monika ;
Rietschel, Marcella ;
McQuillin, Andrew ;
Frank, Josef ;
Kiefer, Falk ;
Schreiber, Stefan ;
Lieb, Wolfgang ;
Soyka, Michael ;
Semmo, Nasser ;
Aigner, Elmar ;
Datz, Christian ;
Schmelz, Renate ;
Brueckner, Stefan ;
Zeissig, Sebastian ;
Stephan, Anna-Magdalena ;
Wodarz, Norbert ;
Deviere, Jacques ;
Clumeck, Nicolas ;
Sarrazin, Christoph ;
Lammert, Frank ;
Gustot, Thierry ;
Deltenre, Pierre ;
Voelzke, Henry ;
Lerch, Markus M. ;
Mayerle, Julia ;
Eyer, Florian ;
Schafmayer, Clemens ;
Cichon, Sven ;
Noethen, Markus M. ;
Nothnagel, Michael ;
Ellinghaus, David ;
Huse, Klaus ;
Franke, Andre ;
Zopf, Steffen ;
Hellerbrand, Claus ;
Moreno, Christophe ;
Franchimont, Denis ;
Morgan, Marsha Y. ;
Hampe, Jochen .
NATURE GENETICS, 2015, 47 (12) :1443-+
[3]   PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis [J].
Burza, Maria Antonella ;
Molinaro, Antonio ;
Attilia, Maria Luisa ;
Rotondo, Claudia ;
Attilia, Fabio ;
Ceccanti, Mauro ;
Ferri, Flaminia ;
Maldarelli, Federica ;
Maffongelli, Angela ;
De Santis, Adriano ;
Attili, Adolfo Francesco ;
Romeo, Stefano ;
Corradini, Stefano Ginanni .
LIVER INTERNATIONAL, 2014, 34 (04) :514-520
[4]   Systematic review with meta-analysis: the I148M variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis [J].
Chamorro, A-J. ;
Torres, J-L. ;
Miron-Canelo, J-A. ;
Gonzalez-Sarmiento, R. ;
Laso, F-J. ;
Marcos, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (06) :571-581
[5]   Trends in Alcoholic Hepatitis-related Hospitalizations, Financial Burden, and Mortality in the United States [J].
Jinjuvadia, Raxitkumar ;
Liangpunsakul, Suthat .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (06) :506-511
[6]   Effects of Age, Sex, Body Weight, and Quantity of Alcohol Consumption on Occurrence and Severity of Alcoholic Hepatitis [J].
Liangpunsakul, Suthat ;
Puri, Puneet ;
Shah, Vijay H. ;
Kamath, Patrick ;
Sanyal, Arun ;
Urban, Thomas ;
Ren, Xiaowei ;
Katz, Barry ;
Radaeva, Svetlana ;
Chalasani, Naga ;
Crabb, David W. .
Clinical Gastroenterology and Hepatology, 2016, 14 (12) :1831-1838
[7]   Trends in the management and burden of alcoholic liver disease [J].
Mathurin, Philippe ;
Bataller, Ramon .
JOURNAL OF HEPATOLOGY, 2015, 62 :S38-S46
[8]   The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): Study protocol for a randomised controlled trial [J].
Morley, K. C. ;
Leung, S. ;
Baillie, A. ;
Haber, P. S. .
CONTEMPORARY CLINICAL TRIALS, 2013, 36 (02) :348-355
[9]   Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease [J].
Romeo, Stefano ;
Kozlitina, Julia ;
Xing, Chao ;
Pertsemlidis, Alexander ;
Cox, David ;
Pennacchio, Len A. ;
Boerwinkle, Eric ;
Cohen, Jonathan C. ;
Hobbs, Helen H. .
NATURE GENETICS, 2008, 40 (12) :1461-1465
[10]   Genetic Variation in the PNPLA3 Gene Is Associated with Alcoholic Liver Injury in Caucasians [J].
Stickel, Felix ;
Buch, Stephan ;
Lau, Katharina ;
Schwabedissen, Henriette Meyer zu ;
Berg, Thomas ;
Ridinger, Monika ;
Rietschel, Marcella ;
Schafmayer, Clemens ;
Braun, Felix ;
Hinrichsen, Holger ;
Guenther, Rainer ;
Arlt, Alexander ;
Seeger, Marcus ;
Mueller, Sebastian ;
Seitz, Helmut Karl ;
Soyka, Michael ;
Lerch, Markus M. ;
Lammert, Frank ;
Sarrazin, Christoph ;
Kubitz, Ralf ;
Haeussinger, Dieter ;
Hellerbrand, Claus ;
Broering, Dieter ;
Schreiber, Stefan ;
Kiefer, Falk ;
Spanagel, Rainer ;
Mann, Karl ;
Datz, Christian ;
Krawczak, Michael ;
Wodarz, Norbert ;
Voelzke, Henry ;
Hampe, Jochen .
HEPATOLOGY, 2011, 53 (01) :86-95